NF-κB drives acquired resistance to a novel mutant-selective EGFR inhibitor
Elena Galvani(University of Parma), Elisa Giovannetti(University of Pisa)
Cited by 31
Related Papers
Molecular basis and rationale for combining immune checkpoint inhibitors with chemotherapy in non-small cell lung cancer
|Drug Resistance Updates|2019|198
Entrectinib: a potent new TRK, ROS1, and ALK inhibitor
|Expert Opinion on Investigational Drugs|2015|153
Applications and clinical trial landscape using Toll-like receptor agonists to reduce the toll of cancer
|npj Precision Oncology|2023|146
Immunotherapy in NSCLC: A Promising and Revolutionary Weapon
|Advances in experimental medicine and biology|2017|143
Harnessing the tumor microenvironment: targeted cancer therapies through modulation of epithelial-mesenchymal transition
|Journal of Hematology & Oncology|2025|128